4th Quarter - Report
STANTON PARK GROUP for VERTEX PHARMACEUTICALS INCORPORATED
Firm
Income
$50,000
Expenses
—
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
access to rare and orphan disease therapeutics; FDA regulatory pathways for pharmaceuticals; awareness of cystic fibrosis; continuous manufacturing processes HR 6, the 21st Century Cures Act; The Senate "Innovation for Healthier Americans"; S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015
| Lobbyist | Covered position, as disclosed |
|---|---|
| JAMES DERDERIAN | — |
| VALERIE HENRY | — |
| RICHARD MATHER RUSSELL | — |
| EMILY SHETTY | — |
| ERIN STRAWN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.